(Total Views: 520)
Posted On: 11/08/2021 7:14:05 AM
Post# of 154867
By all means look.. ALS, like ALZ, isn't a homogeneous disorder.. they're both blanket terms for a range of dysfunction that manifests in a similar way. Don't be dismayed when it's found to be beneficial to only a subset or (most likely) not at all, given that most manifestations involve metabolic disorders within the neuron itself.
And speaking of market size, ALS is niche, at best.. would be phenomenal if LLMab has any beneficial effect for those just diagnosed. There are many who are already past the point of no return, however, and will not consciously move of their own free will, LLMab or no. But surely google told you that already.
And speaking of market size, ALS is niche, at best.. would be phenomenal if LLMab has any beneficial effect for those just diagnosed. There are many who are already past the point of no return, however, and will not consciously move of their own free will, LLMab or no. But surely google told you that already.
Quote:
like JLang refuting my saying there's a small possibility leronlimab would work for MS but it would never work for ALS, but long after that Dr. Recknor said Cytodyn would be looking at MS and ALS
(1)
(0)
